Log in or Sign up for Free to view tailored content for your specialty!
Endocrinology News
Q&A: Screening for type 1 diabetes may help slow disease progression
NEW ORLEANS — In part one of a three-part video exclusive series, Jonathan D. Leffert, MD, talks with Anna Casu, MD, about the preclinical stages of type 1 diabetes and who should be screened for the disease.
Duodenal mucosal resurfacing granted FDA breakthrough label for weight loss maintenance
The FDA granted breakthrough device designation for an endoscopic procedure that resurfaces the duodenum lining to allow for weight maintenance after discontinuation of a GLP-1 receptor agonist, according to an industry press release.
Log in or Sign up for Free to view tailored content for your specialty!
Thyroid autoimmunity may occur in first few years of life for some children
The presence of thyroid autoantibodies may be detected as early as age 10 months for children, and those positive for both thyroid peroxidase and thyroglobulin autoantibodies have a higher risk for thyroid disease, according to study data.
Excess body weight at first cancer diagnosis linked to second malignancy risk
Older adult cancer survivors who were overweight or obese at the time of first primary cancer diagnosis had a higher risk for developing second cancers, according to findings presented at ASCO Annual Meeting.
Diabetes, weight loss drugs emerging as treatment pathway in rheumatology
Drugs used to treat diabetes and obesity, such as GLP-1 receptor agonists, are becoming an important treatment pathway in rheumatology, according to a presenter at the 2024 Association of Women in Rheumatology annual conference.
New risk calculator could reduce eligibility for statins, BP drugs by 16 million US adults
Using the American Heart Association’s new PREVENT risk calculator would mean reducing eligibility for statin and/or antihypertensive therapy by approximately 16 million U.S. adults, researchers reported in JAMA.
DPP-IV, SGLT2 and GLP-1 drugs do not increase risk for diabetic macular edema
Use of a DPP-IV inhibitor, SGLT2 inhibitor or GLP-1 receptor agonist does not increase risk for diabetic macular edema among adults with type 2 diabetes and diabetic retinopathy, according to study data.
FDA warns of adverse events due to overdosing of compounded semaglutide
The FDA is warning providers and patients that dosing errors with compounded injectable semaglutide may be leading to adverse events, according to a press release.
Safety, cost and more: The issues PCPs should consider when prescribing GLP-1s
There are many important factors primary care providers must consider when prescribing popular anti-obesity medications, according to experts.
Multidisciplinary model can cut refracture risk for hospitalized adults with hip fracture
A multidisciplinary care model can reduce the risk for subsequent fractures among adults hospitalized for a hip fracture, according to findings published in Journal of Bone and Mineral Research.
-
Headline News
‘We have a home’: Physician aims to create network of women allergists
November 14, 20245 min read -
Headline News
Diversified portfolios allow for ‘smoother ride’
November 14, 20243 min read -
Headline News
Predelivery concussion linked to increased risk for severe maternal mental illness
November 12, 20242 min read
-
Headline News
‘We have a home’: Physician aims to create network of women allergists
November 14, 20245 min read -
Headline News
Diversified portfolios allow for ‘smoother ride’
November 14, 20243 min read -
Headline News
Predelivery concussion linked to increased risk for severe maternal mental illness
November 12, 20242 min read